Ambrisan 5 Tablet

About Ambrisan 5 Tablet

Ambrisentan is a medicine used to treat pulmonary arterial hypertension, a condition where blood pressure in the lungs is high. Ambrisan 5 is a 5 mg tablet made by Square Pharmaceuticals PLC.

There are 4 brands of Ambrisentan listed in Bangladesh.

What is Ambrisan 5 Tablet?

Ambrisan 5 is a tablet containing the generic medicine ambrisentan, from Square Pharmaceuticals PLC. It belongs to the anti-hypertensive group and works by blocking the action of a natural substance that narrows blood vessels in the lungs. In pulmonary arterial hypertension, blood pressure in the lung arteries is raised, which makes the heart work harder. Ambrisentan helps by relaxing these vessels. Ambrisan 5 is available as a 5 mg tablet. The doctor decides the dose and course for each patient. It is not for everyone, and a specialist should confirm the diagnosis before treatment starts.

Uses of Ambrisan 5

Ambrisan 5 is used to treat pulmonary arterial hypertension, a type of high blood pressure in the lungs. It helps improve the ability to exercise and delays worsening of the condition. It is prescribed for adults after a proper diagnosis. Only a qualified doctor can decide whether this medicine is suitable for you. Do not use it for any other condition or share it with others.

How to use Ambrisan 5

Take Ambrisan 5 exactly as your doctor tells you. The tablet can be taken with or without food. Swallow it with water. Do not change the dose or stop the medicine unless your doctor advises it. If you miss a dose, ask your doctor or pharmacist what to do. Keep all follow-up appointments, because your doctor will check how the medicine is working and may adjust treatment.

Side effects of Ambrisan 5

Some people may notice swelling, especially of the ankles or feet, when taking ambrisentan. Changes in blood test results, such as a fall in haemoglobin, have been seen with medicines of this type. If you develop sudden shortness of breath or swelling that gets worse, contact your doctor promptly. Your doctor may arrange blood tests during treatment. Tell your doctor about any new or unusual symptoms. Ask your pharmacist if you want to know more about possible side effects.

Safety and precautions

Ambrisan 5 must not be used in pregnancy. It may harm an unborn baby, and pregnancy should be ruled out before treatment starts and prevented during treatment and for a period after stopping, as your doctor will explain. Breastfeeding is not recommended while taking it. Tell your doctor if you are pregnant, planning a pregnancy or breastfeeding. People with liver problems, fluid retention or other serious conditions should speak to the doctor first. This medicine is not for children, as its safety and effectiveness in children have not been established. Always ask your doctor before starting or stopping it.

Frequently asked questions

Is Ambrisan 5 safe during pregnancy or breastfeeding?

No. Ambrisan 5 is not to be used during pregnancy because it may harm the baby. Pregnancy should be excluded before starting and prevented during and after treatment as your doctor advises. Breastfeeding is not recommended while taking this medicine. Talk to your doctor if you are pregnant, could become pregnant or are breastfeeding.

What is Ambrisan 5 used for and what kind of medicine is it?

Ambrisan 5 contains ambrisentan, an anti-hypertensive medicine for pulmonary arterial hypertension, which is high blood pressure in the lungs. It helps improve exercise ability and delays worsening of the condition. It is a tablet and should only be used under a doctor's care. The doctor decides if it is right for you.

How should I store Ambrisan 5?

Keep the tablets in a cool, dry place below 30°C. Protect them from light and moisture. Store them in the original container, out of the reach of children. Do not use tablets after the expiry date. If you are unsure about storage, ask your pharmacist.

Can I take Ambrisan 5 with other medicines?

Some medicines can interact with ambrisentan, so tell your doctor or pharmacist about all medicines you take, including those bought without a prescription. Do not start or stop any medicine on your own. Your doctor will check whether any change is needed and will decide the dose and course.

Indications

Ambrisentan is indicated for the treatment of Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise ability and delay clinical worsening.

Pharmacology

Endothelin-1 (ET-1) is a potent autocrine and paracrine peptide. Two receptor subtypes, ETA and ETB, mediate the effects of ET-1 in the vascular smooth muscle and endothelium. The primary actions of ETA are vasoconstriction and cell proliferation, while the predominant actions of ETB are vasodilation, antiproliferation, and ET-1 clearance. Ambrisentan is a high-affinity ETA receptor antagonist with a high selectivity for the ETA versus ETB receptor (>4000-fold). The clinical impact of high selectivity for ETA is not known.

The pharmacokinetics of Ambrisentan (S-Ambrisentan) in healthy subjects are dose proportional. The absolute bioavailability of Ambrisentan is not known. Ambrisentan is absorbed with peak concentrations occurring approximately 2 hours after oral administration in healthy subjects and PAH patients. Food does not affect its bioavailability. In vitro studies indicate that Ambrisentan is a substrate of P-gp. Ambrisentan is highly bound to plasma proteins (99%). The elimination of Ambrisentan is predominantly by non-renal pathways, but the relative contributions of metabolism and biliary elimination have not been well characterized. In plasma, the AUC of 4-hydroxymethyl Ambrisentan accounts for approximately 4% relative to parent Ambrisentan AUC. Thein vivo inversion of S-Ambrisentan to R-Ambrisentan is negligible. The mean oral clearance of Ambrisentan is 38 mL/min and 19 mL/min in healthy subjects and in PAH patients, respectively. Although Ambrisentan has a 15-hour terminal half-life, the mean trough concentration of Ambrisentan at steady-state is about 15% of the mean peak concentration and the accumulation factor is about 1.2 after long-term daily dosing, indicating that the effective half-life of Ambrisentan is about 9 hours.

Dosage & Administration

Adult dose: Initial treatment is 5 mg once daily, and can be increased to 10 mg once daily if 5 mg is tolerated. Ambrisentan may be administered with or without food.

Pediatric patients: The safety and effectiveness of Ambrisentan in pediatric patients have not been established.

Interaction

Multiple dose co-administration of Ambrisentan and Cyclosporine resulted in an approximately 2-fold increase in Ambrisentan exposure in healthy volunteers; therefore, limit the dose of Ambrisentan to 5 mg once daily when co-administered with Cyclosporine.

Contraindications

Ambrisentan may cause fetal harm when administered to a pregnant woman. Ambrisentan is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. Pregnancy must be excluded before the initiation of treatment with Ambrisentan and prevented during treatment and for one month after stopping treatment. Ambrisentan is contraindicated in patients with Idiopathic Pulmonary Fibrosis (IPF) including IPF patients with pulmonary hypertension (WHO Group 3).

Side Effects

Decreases in hemoglobin concentration and hematocrit have followed administration of other endothelin receptor antagonists and were observed in clinical studies with Ambrisentan

Pregnancy & Lactation

Pregnancy Category X. It is not known whether Ambrisentan is excreted in human milk. Breastfeeding while receiving Ambrisentan is not recommended.

Precautions & Warnings

Fluid Retention: Peripheral edema is a known class effect of endothelin receptor antagonists, and is also a clinical consequence of PAH and worsening PAH.

Pulmonary Veno-occlusive Disease: If patients develop acute pulmonary edema during initiation of therapy with vasodilating agents such as Ambrisentan, the possibility of pulmonary veno-occlusive disease should be considered, and if con_rmed. Ambrisentan should be discontinued.

Hematological Changes: Decreases in hemoglobin concentration and hematocrit have followed administration of other endothelin receptor antagonists and were observed in clinical studies with Ambrisentan.

Hepatic impairment: Ambrisentan is not recommended in patients with moderate or severe hepatic impairment.

Storage Conditions

Store in a cool and dry place, below 30°C. Protect from light and moisture.

Alternative brands of Ambrisentan

Other brands with the same generic name, cheapest first.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.